Prostate cancer diagnosis

Monday, 14 March
08:45 - 10:15

Location: Room 14c (ICM, Level 1)

Chairs: N. Al-Hamdani, Baghdad (IQ)
F.M.J. Debruyne, Arnhem (NL)
V. Scattoni, Milan (IT)

Aims and objectives of this presentation
This session is aiming to find the best and specific way for early diagnosis and detection of prostate cancer and the best way to prevent the disease if possible.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*776 Prostate cancer incidence and cardiovascular mortality among users of testosterone replacement therapy in the Finnish Prostate Cancer Screening Trial
By: Murtola T.1, Rytkönen J.2, Talala K.3, Taari K.4, Tammela T.2, Auvinen A.5
Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Finnish Cancer Registry, Dept. of Statistics, Helsinki, Finland, 4University of Helsinki, Medical School, Helsinki, Finland, 5University of Tampere, School of Health Sciences, Tampere, Finland

*777 The impact of age-adjusted Charlson comorbidity index and age-adjusted prostate cancer specific comorbidity index in men underwent radical prostatectomy: A competing risk analysis of long-term survival data
By: Kang D.H.1, Lee J.Y.1, Jang W.S.1, Kang H.W.2, Kwon J.K.1, Rha K.H.2, Cho N.H.3, Oh C.K.4, Choi Y.D.1, Hong S.J.1, Cho K.S.1
Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, 2Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, 3Yonsei University College of Medicine, Dept. of Pathology, Seoul, South Korea, 4Inje University College of Medicine, Dept. of Urology, Busan, South Korea

*778 Increase prostate cancer detection rate from 12- to 18-core prostate biopsy in patients with serum prostate-specific antigen level of 4.0-20.0 ng/ml
By: Wang B-R.1, Chen C.C.2, Ou Y-C.2
Institutes: 1Taichung Arm Force General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan, 2Taichung Veterans General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan

*779 Comparison of MRI/ultrasound-fusion-biopsy to systematic prostate biopsy in prediction of final histopathology in prostatectomy specimen
By: Borkowetz A.1, Platzek I.2, Toma M.3, Renner T.1, Fröhner M.1, Zastrow S.1, Wirth M.1
Institutes: 1University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, 2University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, 3University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany

*780 Minimizing the Gleason score upgrade from biopsy to prostatectomy specimen through mpMRI and template mapping fusion biopsy
By: Gross O., Neuhaus L., Mortezavi A., Sulser T., Eberli D.
Institutes: University Hospital Zurich, Dept. of Urology, Zürich, Switzerland
**Natural history of prostatic precancerous lesions: When to re-biopsy?**

By: Oderda M.1, Agnello M.1, Barale M.1, Falcone M.1, Marra G.1, Preto M.1, Daniele L.2, Pacchioni D.2, Delsedime L.2, Nicolaiew N.3, Joniau S.3, De La Taille A.4, Gontero P.1

**Institutes:** University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, 2 A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, 3 University Hospitals of Leuven, Dept. of Urology, Leuven, Belgium, 4 C.H.U. Henri Mondor, Dept. of Urology, Creteil, France

---

**Assessing the role of time from prostate cancer diagnosis to radical prostatectomy: Can surgery be postponed safely?**


**Institutes:** IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy

---

**High-resolution magnetic resonance imaging differentiates between normal histomorphological signatures and prostate cancer in the resected prostate gland**

By: Durand M.1, Jain M.2, Robinson B.3, Aronowitz E.4, El Douahy Y.2, Leung R.2, Sherr D.2, Ng A.4, Donzeau D.5, Amiel J.5, Pascal S.4, Villers A.6, Ballon D.4

**Institutes:** 1 Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, INSERM U1189, Dept. of Urology, Nice, France; 2 Weill Medical College of Cornell University, Dept. of Pathology, New York, United States of America; 3 Weill Medical College of Cornell University, Dept. of Radiology, New York, United States of America; 4 Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, Dept. of Urology, Nice, France; 5 CHU Lille, Université De Lille, INSERM U1189, Dept. of Urology, Lille, France

---

**Impact of PI-RADS version 2 on MRI diagnosis for extracapsular extension of prostate cancer: A multireader study**

By: Matsuoka Y.1, Ishioka J.1, Tanaka H.2, Inoue M.1, Ito M.1, Yoshida S.1, Yokoyama M.1, Numao N.1, Saito K.1, Fujii Y.1, Kihara K.1

**Institutes:** 1 Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan; 2 Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

---

**Limitations in elastography based prostate biopsy**

By: Grindei-Nevrincean M.1, Schiffmann J.1, Tian Z.2, Yassin D-J.1, Steinwender T.3, Leyh-Bannurah S-R.2, Randazzo M.2, Kwiatkowski M.3, Karakiewicz P.I.2, Hammerer P.1, Manka L.1

**Institutes:** 1 Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany; 2 University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada; 3 Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland

---

**Phenotypic and molecular characterization of circulating tumor cells (EGFR and AR) and its correlation with prostate biopsy in early-stage prostate cancer**

By: Puche Sanz I.1, Flores-Martín J.1, Vázquez Alonso F.1, Serrano Fernández M.J.2, Cózar Olmo J.M.1

**Institutes:** 1 Complejo Hospitalario Universitario De Granada, Dept. of Urology, Granada, Spain; 2 Centro Pfizer-Universidad De Granada-Junta De Andalucía De Genómica E Investigación Oncológica (GENY, Dept. of Circulating Tumor Cells, Granada, Spain